Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 18/20 | 0.69 |
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.69 |
| ▸ | HTR3A | P46098 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL405574 | 0.95 | HRH4 (0.69) | HRH4HRH3HTR3AKDM4EALDH1A1 | |
| SCHEMBL404275 | 0.91 | HRH4 (0.74) | HRH4HRH3HTR3A | |
| SCHEMBL405875 | 0.87 | HRH4 (0.61) | HRH4HRH3KDM4EALDH1A1HPGD | |
| SCHEMBL404233 | 0.87 | HRH4 (0.68) | HRH4HRH3HTR3A | |
| SCHEMBL12224846 | 0.86 | HRH4 (0.67) | HRH4HRH3HTR3AKDM4EALDH1A1 | |
| SCHEMBL404250 | 0.86 | HRH4 (0.67) | HRH4HRH3HTR3AKDM4EALDH1A1 | |
| SCHEMBL405218 | 0.85 | HRH4 (0.68) | HRH4HRH3HTR3A | |
| SCHEMBL12224784 | 0.84 | HRH4 (0.64) | HRH4HRH3HTR3A | |
| SCHEMBL342019 | 0.84 | HRH4 (0.64) | HRH4HRH3HTR3A | |
| SCHEMBL12224840 | 0.83 | HRH4 (0.68) | HRH4HRH3HTR3AKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065187-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | ALCON RESEARCH, LTD (US) | 2012-03-15 | — | — | US | disclosed |
| US-20110257137-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2011-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065187-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | HRH4, HRH3, HRH2 | HRH4 1/4885HRH3 2/4885HTR3A 153/4885 |
| US-20110257137-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | HRH4, HRH3, HRH2 | HRH4 1/4885HRH3 2/4885HTR3A 153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.